Contact
searchSearch
HMP Global

Breast Cancer Topic Center

Featured Article

Conference Coverage
Medicaid Expansion Linked to Early Breast Cancer Treatment, Survival Among Young Adult Women
06/02/2023
Hannah Musick
A new study showed Medicaid expansion in the United States was associated with increased receipt of timely, guideline-concordant breast cancer treatment and improved survival for young adult women.
A new study showed Medicaid expansion in the United States was associated with increased receipt of timely, guideline-concordant breast cancer treatment and improved survival for young adult women.
A new study showed Medicaid...
06/02/2023
First Report Managed Care
Conference Coverage
Breast Cancer Data Discrepancies Found Across National Tumor Registries
06/02/2023
Hannah Musick
Researchers at the 2023 ASCO Annual Meeting compared data on breast cancer cases in 3 national databases to identify differences in case coverage.
Researchers at the 2023 ASCO Annual Meeting compared data on breast cancer cases in 3 national databases to identify differences in case coverage.
Researchers at the 2023 ASCO...
06/02/2023
First Report Managed Care
News
Lower Incidence of Breast Cancer Among Female Veterans Deployed During Post-9/11 Conflicts
02/02/2023
Maria Asimopoulos
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than...
02/02/2023
Veterans Health Today
From Veterans Health Today
Conference Coverage
Black Women More Likely to Experience Dose Delays, Worse Outcomes in Triple-Negative Breast Cancer Treatment
06/10/2022
Maria Asimopoulos
Findings presented at the 2022 ASCO Annual Meeting suggest there are disparities in care for Black women with triple-negative breast cancer as compared with White women.
Findings presented at the 2022 ASCO Annual Meeting suggest there are disparities in care for Black women with triple-negative breast cancer as compared with White women.
Findings presented at the 2022...
06/10/2022
First Report Managed Care
Conference Coverage
Symptom-Related Quality of Life in Patients Treated With First-Line Ribociclib vs Ademaciclib
06/10/2022
Maria Asimopoulos
Investigators at the 2022 ASCO Annual Meeting compared symptoms in patients receiving either ribociclib or abemaciclib in combination with endocrine therapy in the front-line setting for HR+/HER2- advanced breast cancer.
Investigators at the 2022 ASCO Annual Meeting compared symptoms in patients receiving either ribociclib or abemaciclib in combination with endocrine therapy in the front-line setting for HR+/HER2- advanced breast cancer.
Investigators at the 2022 ASCO...
06/10/2022
First Report Managed Care
Conference Coverage
Treatment Costs, Care of Patients With Metastatic Breast Cancer in the United States
06/10/2022
Samantha Matthews
Costs related to metastatic breast cancer vary by receptor subtype as well as the number of years postdiagnosis, according to research presented at the 2022 ASCO Annual Meeting.
Costs related to metastatic breast cancer vary by receptor subtype as well as the number of years postdiagnosis, according to research presented at the 2022 ASCO Annual Meeting.
Costs related to metastatic...
06/10/2022
First Report Managed Care
Conference Coverage
Assessing Alpelisib, Fulvestrant Benefit Among Patients With Advanced Breast Cancer
06/07/2022
Samantha Matthews
“Clinical benefit was maintained regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance, consistent with alpelisib targeting the PIK3CA driver oncogene,” wrote researchers.
“Clinical benefit was maintained regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance, consistent with alpelisib targeting the PIK3CA driver oncogene,” wrote researchers.
“Clinical benefit was maintained...
06/07/2022
First Report Managed Care
Conference Coverage
Real-World Data Suggests Palbociclib Efficacious for Treating HR+/HER2- Advanced Breast Cancer
06/06/2022
Maria Asimopoulos
A multicenter study of real-world practices in China showed palbociclib plus endocrine therapy was efficacious among patients with HR+/HER2- advanced breast cancer.
A multicenter study of real-world practices in China showed palbociclib plus endocrine therapy was efficacious among patients with HR+/HER2- advanced breast cancer.
A multicenter study of...
06/06/2022
First Report Managed Care
Conference Coverage
Effect of Ribociclib Dose Modifications on Overall Survival in Patients With HR+/HER2- Advanced Breast Cancer
06/06/2022
Samantha Matthews
Researchers at the 2022 ASCO Annual Meeting shared promising results from a trial examining the effect of dosage modifications on overall survival among postmenopausal patients with HR+/HER2- advanced breast cancer.
Researchers at the 2022 ASCO Annual Meeting shared promising results from a trial examining the effect of dosage modifications on overall survival among postmenopausal patients with HR+/HER2- advanced breast cancer.
Researchers at the 2022 ASCO...
06/06/2022
First Report Managed Care
Icario logo
Commentary
New Research to Bridge Gaps in Care for Breast Cancer Amid COVID-19
09/01/2021
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario...
09/01/2021
First Report Managed Care
William Audeh, MD, MS
Videos
Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer
06/11/2021
Julie Gould
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief...
06/11/2021
First Report Managed Care

Newsfeed

News
Lower Incidence of Breast Cancer Among Female Veterans Deployed During Post-9/11 Conflicts
02/02/2023
Maria Asimopoulos
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than...
02/02/2023
Veterans Health Today
Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
News
Differences in OUD Treatment Coverage Across Medicaid Managed Care Plans From 2015 to 2019
05/26/2026
Rebecca Amrick
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Comorbidities Increase Clinical and Economic Burden for Patients With Chronic Kidney Disease
05/22/2026
Rebecca Amrick
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden...
05/22/2026
First Report Managed Care
News
Pembrolizumab Plus Chemotherapy Improves Survival in mNSCLC at Higher Cost
05/22/2026
Rebecca Amrick
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy...
05/22/2026
First Report Managed Care
Behind the Bill
Congress Targets Enforcement Gaps in the No Surprises Act
05/22/2026
Hannah Musick
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to...
05/22/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care
News
The Effect of Nephologist Affiliation on PD Utilization for Patients With ESKD
05/20/2026
Rebecca Amrick
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that...
05/20/2026
First Report Managed Care
News
Ponatinib Demonstrates Greater Clinical Benefit Than Imatinib but With Significantly Higher Care Costs
05/20/2026
Rebecca Amrick
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor...
05/20/2026
First Report Managed Care
News
Severe Alcohol-Associated Hepatitis Raises Health Care Costs Across Multiple Care Settings
05/18/2026
Rebecca Amrick
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for...
05/18/2026
First Report Managed Care

Insights

Icario logo
Commentary
New Research to Bridge Gaps in Care for Breast Cancer Amid COVID-19
09/01/2021
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario...
09/01/2021
First Report Managed Care
William Audeh, MD, MS
Videos
Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer
06/11/2021
Julie Gould
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief...
06/11/2021
First Report Managed Care
Headshot of Dr Joanne Mortimer on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Considering Patient Needs to Ensure Effective Treatments and Reduce Payer Costs
06/03/2021
Julie Gould
Joanne Mortimer, MD, director of women’s cancer programs at City of Hope, discusses the unique challenges of treating breast cancer, the importance of patient-centered treatment, and what payers can do to better accommodate patient needs...
Joanne Mortimer, MD, director of women’s cancer programs at City of Hope, discusses the unique challenges of treating breast cancer, the importance of patient-centered treatment, and what payers can do to better accommodate patient needs...
Joanne Mortimer, MD, director of...
06/03/2021
First Report Managed Care
Podcasts
The Critical Need for Continued Research in Breast Cancer
05/06/2021
Alison Conlin, MD, MPH, medical oncologist, Providence Cancer Institute, stresses the importance of research in breast cancer care and says the stressors and outcomes of the pandemic share similarity to those of a cancer-related outcomes.
Alison Conlin, MD, MPH, medical oncologist, Providence Cancer Institute, stresses the importance of research in breast cancer care and says the stressors and outcomes of the pandemic share similarity to those of a cancer-related outcomes.
Alison Conlin, MD, MPH, medical...
05/06/2021
First Report Managed Care
Podcasts
Common Treatment Challenges Among Patients With Breast Cancer and How it Compares to Other Cancer Types
02/19/2021
William Rayford Gwin III, MD, medical oncologist, Seattle Cancer Care Alliance, breaks down some common challenges in treating breast cancer that make it unique compared to other types of cancer, and provides some risk reducing strategies for...
William Rayford Gwin III, MD, medical oncologist, Seattle Cancer Care Alliance, breaks down some common challenges in treating breast cancer that make it unique compared to other types of cancer, and provides some risk reducing strategies for...
William Rayford Gwin III, MD,...
02/19/2021
First Report Managed Care
Podcasts
Navigating Through Breast Cancer Care With the Entire Care Team and Addressing Medication Costs
01/07/2021
Jairam Krishnamurthy, MD, FACP, assistant professor of medicine, University of Nebraska Medical Center, reviews what it is like to navigate through breast cancer care with the whole care team—including the patient, pharmacists, other...
Jairam Krishnamurthy, MD, FACP, assistant professor of medicine, University of Nebraska Medical Center, reviews what it is like to navigate through breast cancer care with the whole care team—including the patient, pharmacists, other...
Jairam Krishnamurthy, MD, FACP,...
01/07/2021
First Report Managed Care
Podcasts
Identifying Risk-Reducing Strategies for Breast Cancer and How Payers Can Address the Costs of Medications
12/09/2020
Victor G Vogel, MD, medical oncologist, Geisinger Health System, discusses a variety of risk reducing strategies for breast cancer, including why some are “overdue,” explains why there is a lack in the uptake of medications among patients...
Victor G Vogel, MD, medical oncologist, Geisinger Health System, discusses a variety of risk reducing strategies for breast cancer, including why some are “overdue,” explains why there is a lack in the uptake of medications among patients...
Victor G Vogel, MD, medical...
12/09/2020
First Report Managed Care

Interactive Features

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use